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R E V I E W
Abstract: Inhaled human insulin (Exubera®) is a rapid-acting regular human insulin
administered by oral inhalation before meals. It provides a non-invasive alternative to multiple
subcutaneous injections for the treatment of hyperglycemia in adult patients with type 1 and
type 2 diabetes. Compared with subcutaneous rapid-acting insulin analogs, Exubera provides
equivalent HbA
1c
 control. As a monotherapy or in combination with oral agents, Exubera also
provides greater glycemic control than oral agents alone, at least in patients with high levels
of HbA
1c
. Exubera demonstrates improved patient satisfaction compared with subcutaneous
insulin or oral agents alone. When offered as a treatment option together with standard
treatments in uncontrolled patients naïve to insulin, Exubera increases acceptance of insulin
therapy three-fold compared with patients offered standard regimens only. Exubera is well
tolerated in comparison to subcutaneous insulin, with a similar incidence of mild to moderate
hypoglycemia. Although cough is a common adverse effect early in therapy, this leads to
treatment discontinuations in less than 1% of patients. Despite an increased incidence of
insulin antibodies compared with subcutaneous administration, and a consistent but minor
impact on pulmonary function, long-term safety data of up to 4 years continue to support the
safety profile of Exubera.
Keywords: Exubera, inhaled human insulin, hyperglycemia, diabetes
Introduction
Diabetes mellitus is a major contributor to the global disease burden and is currently
experiencing a dramatic rise in prevalence. The World Health Organization forecasts
a virtual doubling in number of those currently affected to more than 350 million
cases by 2030 (WHO 2006). Type 2 diabetes will account for most of the projected
increase, which reflects not only the demographics of an aging population, but also
increasing numbers of overweight and obese people who are at increased risk of
diabetes (Gungor and Arslanian 2002).
Compared with the healthy population, diabetes sufferers are at considerable
increased risk of morbidity from cardiovascular, cerebrovascular, and peripheral
vascular disease, leading to outcomes such as myocardial infarction, stroke and limb
amputation (Khaw et al 2004). Individuals with diabetes have a two- to four-fold
increased risk of experiencing a cardiovascular event compared with age-matched
individuals without diabetes, while the risk of mortality following myocardial
infarction is approximately two- to three-fold greater (American Diabetes Association
1998). Cardiac risk factors, such as smoking, hypertension, high cholesterol and
excessive weight take on increased significance in the patient with diabetes, and
should be treated as aggressively as for the non-diabetic individual with a prior
myocardial infarction (Goldfine and Goldfine 2003). In addition to life-threatening
macrovascular complications typical of type 2 diabetes, serious complications of the
microvasculature, such as neuropathy, nephropathy, and retinopathy, can adversely
affect quality of life while imposing a heavy burden on healthcare systems (Stratton
et al 2000; Khaw et al 2004).
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Improved blood glucose control is an important
therapeutic goal in diabetes, with intensive control known
to be important for reducing the risk of microvascular disease
(Reichard et al 1991; UKPDS 1996) (Table 1). Initial therapy
with oral antidiabetic agents can be effective at achieving
glycemic control in type 2 diabetes, but as a chronic disease
marked by a progressive course, most patients eventually
require insulin therapy for effective control (Turner et al
1999; Cook et al 2005). Physicians typically rely on a
stepwise approach to achieving glycemic control, beginning
with diet and exercise, followed by initiation of single agent
oral antidiabetic therapy, and progressing to combination
oral agents and subsequently insulin (Campbell 2000)
(Figure 1). However, with this approach, patients may be
receiving suboptimal glycemic control for many months and
even years before they are progressed to the next level of
treatment (Campbell 2000; Brown and Nichols 2003). A
more proactive approach to glucose management is needed
to assist not only the estimated 60% of patients currently
failing to reach recommended glycemic targets, but also to
more rapidly achieve glycemic targets in all patients
(Campbell 2000; Del Prato et al 2005).
Importance of insulin therapy
Lifestyle intervention in the form of diet and exercise
regimens is an integral component of diabetes management,
but adherence to such regimens is often difficult to achieve
and maintain, and most patients with type 2 diabetes will
require pharmacologic intervention for glycemic control
(Mudaliar and Henry 1999).
Randomized, controlled trials have provided compelling
evidence that achieving strict glycemic control can reduce
the long-term complications of diabetes (DCCT 1993;
Malmberg 1997; UKPDS 1998; Shichiri et al 2000). In the
Diabetes Control and Complications Trial (DCCT), patients
with type 1 diabetes with and without mild retinopathy at
baseline were assigned to either intensive insulin treatment
involving frequent blood glucose monitoring or
conventional therapy. In the primary prevention cohort, there
was a strong relationship between risk of retinopathy and
mean glycosylated hemoglobin (HbA1c) levels. For each
10% decrease in HbA1c, such as from 8.0% to 7.2%, there
was a 39% decrease in risk over the range of HbA1c values.
Furthermore, intensive insulin therapy delivered by external
pump or by three-times-daily injections was associated with
a 47% reduction in the development of severe retinopathy
in patients with prior retinopathy at baseline and a 76%
reduction in risk of developing retinopathy in the primary
Table 1  Recommended targets for glycemic control
Target for most patients HbA1c Fasting plasma glucose 2-hour postprandial plasma glucose
(%) (mmol/L [mg/dL]) (mmol/L [mg/dL])
ADA1 <7.0 5.0–7.2 (90–130) <10.0 (180)
IDF2 <6.5 <6.0 (110) <8.0 (145)
NICE3 6.5–7.5a
Normal range ≤6.0 4.0–6.0 (70–110) 5.0-8.0 (90–145)
aBased on the risk of macrovascular and microvascular complications. In general, the lower target HbA1c is preferred for those people at significant risk of
macrovascular complications, but higher targets are necessary for those at risk of hypoglycemia.1American Diabetes Association.2International Diabetes
Federation.3National Institute of Clinical Excellence.
Figure 1  Conservative versus proactive management of type 2 diabetes: (A)
traditional stepwise approach to long-term glycemic control and (B) early
combination approach. Reproduced with permission from Campbell IW. 2000.
Need for intensive early glycaemic control in patients with type 2 diabetes. Br J
Cardiol, 7:625–31.
Abbreviations: HbA1c, glycosylated hemoglobin; OAD, oral antidiabetic drug.
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prevention cohort, as compared with conventional therapy
involving once- or twice-daily insulin injections (DCCT
1993). The UK Prospective Diabetes Study (UKPDS)
evaluated the impact of intensive insulin or oral antidiabetic
therapy versus diet alone on microvascular and
macrovascular complications in patients with newly
diagnosed type 2 diabetes. Projections suggested that for
each 1% reduction in mean HbA1c there would be a
corresponding 37% reduction in the risk of microvascular
complications, a 14% lower rate of myocardial infarction,
and 21% fewer deaths related to diabetes (Stratton et al 2000)
(Figure 2).
While DCCT, UKPDS and other studies have been useful
in demonstrating the overall benefit of insulin treatment in
preventing the onset and/or progression of complications
in patients with both type 1 and type 2 diabetes, the same
studies also lend support to early implementation of insulin
(DCCT 1993; UKPDS 1998; Shichiri et al 2000; DCCT/
EDIC 2002). Early and intensive pharmacologic intervention
takes on increased significance given that postprandial
excursions, which appear to be more adequately controlled
by insulin compared with oral antidiabetic agents, have been
linked to increased cardiovascular risk (Malone et al 2003;
Ceriello et al 2004; Esposito et al 2004). Increasingly,
evidence suggests that insulin has a protective role against
endothelial dysfunction, which in the context of postprandial
hyperglycemia may prevent progression of atherosclerosis
(Ceriello et al 2004; Esposito et al 2004). Studies of intensive
insulin therapy versus conventional treatment for tight
glycemic control in high-risk patients with or without
diabetes have demonstrated a survival benefit for intensive
insulin therapy, which is putatively related to anti-
inflammatory, anti-thrombogenic and anabolic effects of
insulin (Malmberg et al 1999; Van den Berghe et al 2001;
Lazar et al 2004).
Achievement of glycemic targets
One of the main goals of diabetes management is to achieve
blood glucose levels that are as close to the normal range as
possible in order to prevent the development of diabetic
complications (Turner et al 1999). In contrast to
microvascular disease, evidence suggests there is a
continuous relationship between blood glucose
concentrations and macrovascular disease, which continues
even below diagnostic threshold levels for diabetes (Khaw
et al 2004). However, despite increasingly stringent
guidelines, over 60% of patients throughout the world are
currently not reaching glycemic targets (Del Prato et al
2005). In a 6-month study evaluating physician records of
7000 patients with type 2 diabetes from 8 European
countries, just 31% of patients achieved good glycemic
control defined as HbA1c ≤6.5%, while the mean HbA1c
value across the entire study population was 7.5% (Liebl et
al 2002). Similarly, in a US study sample derived from the
National Health and Nutrition Examination Survey
(NHANES), glycemic control rates defined as HbA1c level
<7% declined from 44.5% between 1988 and 1994 to 35.8%
between 1999 and 2000 (Koro et al 2004). A further
worrying trend to have emerged from this study was the
decline in insulin usage from 24.2% to 16.4% of those
surveyed over the same period (Koro et al 2004).
Physicians often wait too long to move patients from
oral antidiabetic therapy to insulin (Hayward et al 1997;
Nathan 2002). In addition to a lack of consensus among
physicians as to when and how intensive insulin therapy
should be initiated, the delay in using insulin may also relate
to concerns that insulin therapy promotes insulin resistance,
increases the risk of cardiovascular events, is not effective
at controlling hyperglycemia, and is associated with dramatic
weight gain (Riddle 2002). However, such concerns are
unfounded, with recent findings demonstrating that insulin
safely improves glycemic control without promoting
increased hypoglycemia or weight gain (Hayward et al 1997;
Wright et al 2002; Riddle 2002). Moreover, the tendency
among physicians to reserve insulin therapy for those
patients who are inadequately controlled with diet and oral
antidiabetic agents means that a high proportion of patients
receiving insulin will have pre-existing co-morbidities and
complications due to longstanding disease (Liebl et al 2002).
In recognizing the barriers to achieving current glycemic
targets, the Global Partnership for Effective Diabetes
Management now recommends that combination therapy
Figure 2  In the UK Prospective Diabetes Study (UKPDS), each 1% reduction
in HbA1c was projected to produce significant reductions in the risk of diabetes-
related complications (Stratton et al 2000).
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or insulin should be initiated immediately for all patients
with HbA1c ≥9% at diagnosis (Del Prato et al 2005). In
addition, most patients with established diabetes who are
unable to achieve recommended glycemic goals using oral
antidiabetic agents are candidates for insulin therapy.
Development of inhaled insulins
The potential benefits of offering subcutaneous insulin
therapy in patients with diabetes are frequently limited due
to injection aversion, psychological resistance to another
therapy following prior failure to control glycemia, concerns
over complications and pain, and fear of disease progression,
among others (Hunt et al 1997; Korytkowski 2002; Funnell
et al 2004; Heinemann 2004; Freemantle et al 2005).
Moreover, reluctance to initiate insulin therapy is often
shared by patients and physicians alike (Korytkowski 2002;
Funnell et al 2004). As a result, adherence to an insulin
regimen can be difficult to achieve and maintain, thereby
compromising optimal glycemic control (Royle et al 2003).
The successful development of an inhalable, rapid-acting
insulin that represents a noninvasive alternative to multiple
daily subcutaneous insulin injections promises to change
the management of diabetes. Made possible by advances in
inhaler devices and insulin formulation technology, there
are now several insulin inhalation systems at varying stages
of clinical development (Patton et al 2004). Inhaled human
insulin (Exubera® (insulin human [rDNA origin]) Inhalation
Powder), developed by Pfizer Inc in collaboration with
Nektar Therapeutics, has received approval in both the US
and the European Union for the control of hyperglycemia
in adult patients with type 1 or type 2 diabetes. Exubera
consists of a fine, dry-powder formulation of regular human
insulin packaged in unit doses of 1 or 3 mg for inhalation in
blister packs, which are administered via a unique and
reusable mechanical pulmonary inhaler. Clinical experience
to date indicates that Exubera has the potential to offer
treatment and quality of life benefits to patients with
diabetes, which are achieved through the delivery of a
systemic dose of insulin via the pulmonary route while
fulfilling the appropriate pharmacokinetic and
pharmacodynamic prof iles to effectively control
hyperglycemia (Patton et al 2004).
Clinical pharmacology
The pharmacokinetic profile of Exubera closely mimics the
natural pattern of postprandial insulin secretion that is also
achieved with rapid-acting subcutaneous insulin analogs,
but not regular human insulin (Rave et al 2005). Whereas
regular insulin has a relatively slow onset of action and a
prolonged duration of action when injected subcutaneously,
resulting in suboptimal control of postprandial
hyperglycemia, Exubera is associated with an onset of action
that is at least as fast as the subcutaneously injected rapid-
acting insulin analog, insulin lispro (Rave et al 2005). Peak
serum insulin concentrations following inhalation of
Exubera, or subcutaneous administration of insulin lispro
or regular insulin reflect glucose consumption rates, with
Exubera attaining peak serum levels at a faster rate than
either insulin lispro or regular insulin (Rave et al 2005).
In addition to offering a rapid onset of action, the longer
duration of action of Exubera relative to insulin lispro may
be better suited to postprandial glucose control. Clinical
studies have suggested that the duration of action of
subcutaneously administered insulin analogs is too short to
provide adequate postprandial control, as indicated by rising
glucose levels post-absorption (Del Sindaco et al 1998;
Ciofetta et al 1999; Rave et al 2005). The reason for the
prolonged metabolic action of inhaled insulin relative to
subcutaneously administered rapid-acting insulin analogs
is unclear, but may relate to the size-dependent absorption
and dissociation characteristics of inhaled insulin particles
(Rave et al 2005).
Smoking has a significant impact on the absorption of
Exubera, with pharmacokinetic analysis indicating that
absorption of inhaled insulin is increased in smokers relative
to non-smokers (Becker et al 2006). This effect is partly
reversed after only 1 week of smoking cessation, but reverts
back to absorption levels typical of chronic smokers within
a couple of days of smoking resumption. Due to the
increased risk of hypoglycemia in smokers as a consequence
of short-term changes in insulin availability, patients with
diabetes should abstain from smoking before and during
treatment with Exubera (Becker et al 2006).
Variable response to insulin among patients with diabetes
is an important aspect of insulin delivery in the context of
clinical practice. In a comparison of Exubera and
subcutaneous insulin in obese, elderly patients with type 2
diabetes, within-subject variability at doses producing
comparable systemic insulin exposure over 6 hours was at
least as good for inhaled insulin as for subcutaneous
administration (Henry et al 2003). Thus, inhaled insulin
offers the benefits of non-invasive administration and a
pharmacokinetic-pharmacodynamic profile that combines
the relative advantages of rapid-acting insulin analogs (rapid
onset of action) and regular insulin (prolonged metabolic
action), while also offering consistent absorption in diverse
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patient groups making it suitable as an insulin replacement
therapy (Henry et al 2003; Rave et al 2005).
Efficacy and tolerability
Efficacy
Randomized clinical trials in patients with type 1 and type
2 diabetes have shown that Exubera achieves and maintains
effective glycemic control that is comparable to
subcutaneously administered regular and NPH insulin
(Cefalu et al 2001; Skyler et al 2001; Hollander et al 2004;
Quattrin et al 2004; Dumas et al 2005; Skyler et al 2005).
In the original proof-of-concept study, 53 patients with type
2 diabetes for a mean duration of 11 years were randomized
in an open-label manner to either continue to receive
subcutaneous insulin therapy or to switch to inhaled insulin
for a period of 12 weeks (Cefalu 2001; Cefalu et al 2001;
Cappelleri et al, 2002). Patients in the experimental group
received preprandial inhaled insulin plus a bedtime
subcutaneous ultralente insulin injection. Inhaled insulin
treatment significantly improved HbA1c compared with
baseline, achieving glycemic control that was at least as
good as conventional treatment. In a similar study conducted
in patients with type 1 diabetes, changes in HbA1c and
glycemic control were indistinguishable for inhaled versus
conventional insulin treatment (Skyler et al 2001). In Phase
III randomized controlled trials of patients with type 1 and
type 2 diabetes, Exubera achieved similar reductions in
HbA1c as subcutaneous insulin. However, in type 1 diabetes,
Exubera was more effective than subcutaneous insulin in
reducing fasting and postprandial plasma glucose, while in
type 2 diabetes, more patients treated with Exubera
compared with subcutaneous insulin achieved an HbA1c
level of <7.0% after 6 months (Hollander et al 2004; Quattrin
et al 2004).
In clinical trials of patients with type 2 diabetes
inadequately controlled with oral antidiabetic agents alone,
patients assigned to Exubera monotherapy or in combination
with oral agents had greater improvement in HbA1c
compared with patients treated with oral agents alone (Weiss
et al 2003; Rosenstock et al 2005; Barnett et al 2006a, b).
One of these trials, a 6-month randomized open-label study
comparing inhaled insulin with metformin as adjunctive
therapy, recruited patients typically seen in clinical practice
with a range of BMI values and a baseline HbA1c value of
at least 8.0% (Barnett et al 2006a). Compared with
metformin plus a sulfonylurea, inhaled insulin in
combination with a sulfonylurea produced a significantly
greater reduction in HbA1c in patients with a baseline HbA1c
value >9.5%. Two 3-month investigations provided further
demonstration of a benefit for inhaled insulin (Weiss et al
2003; Rosenstock et al 2005). In both these studies the
percentage of patients achieving HbA1c <7.0% was higher
for those assigned to a regimen that included inhaled insulin
compared with oral antidiabetic agents alone.
Physicians continue to place their greatest emphasis on
fasting plasma glucose and HbA1c levels in the management
of type 2 diabetes. However, the disease is characterized by
a gradual decline in insulin secretion in response to nutrient
loading, making the third component of the glucose triad –
postprandial plasma glucose – an important consideration
for effective disease management. Evidence is increasingly
supporting a more prominent role for postprandial plasma
glucose regulation, with postprandial hyperglycemia
contributing at least 70% of the overall glycemic load in
patients with an HbA1c level of around 7.0% (Leiter et al
2005). In clinical trials, Exubera has been shown to
effectively control HbA1c concentrations in patients with
type 1 or type 2 diabetes, while there is also evidence that it
improves postprandial plasma glucose and fasting plasma
glucose levels compared with oral agents alone or
subcutaneous insulin regimens (Hollander et al 2004;
Quattrin et al 2004; Weiss et al 2003; Rosenstock et al 2005;
Skyler et al 2005).
Tolerability
Hypoglycemia and cough are the main adverse effects
reported in clinical trials of Exubera (Odegard and Capoccia
2005). Consistent with the incidence of hypoglycemia with
subcutaneous insulin use, hypoglycemia is the most frequent
adverse effect for Exubera with an event rate of around 0.3
to 1.4 events per patient-month in type 2 diabetes, and 5.5
to 9.3 events per patient-month in type 1 diabetes (Cefalu
et al 2001; Skyler et al 2001; Hollander et al 2004; Quattrin
et al 2004; Weiss et al 2003; Skyler et al 2005; Barnett et al
2006). However, both the frequency and nature of
hypoglycemia with Exubera use are comparable to those
with subcutaneous insulin, with most events being mild to
moderate in severity (Odegard and Capoccia 2005). Mild
cough is not an unexpected finding with inhaled insulin and
occurs more frequently than with subcutaneous insulin,
although symptoms decrease over time (Hollander et al
2004; Quattrin et al 2004). Fewer than 1% of patients
discontinue therapy due to cough (Quattrin et al 2004;
Barnett et al 2006).
As for any therapeutic protein, anti-insulin antibodies
may develop during treatment with Exubera, with the
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primary concern being the potential for effects on insulin
resistance (Odegard and Capoccia 2005). In clinical trials,
anti-insulin antibodies developed more frequently and mean
titers were higher in patients who switched from
subcutaneous treatment to Exubera compared with those
who remained on subcutaneous insulin (Hollander et al
2004; Quattrin et al 2004; Rosenstock et al 2005; Skyler et
al 2005). Antibody titers were higher in patients with type 1
diabetes compared with type 2 diabetes, and reached a
plateau within 6–12 months of exposure (Fineberg et al
2005; Barnett et al 2006). However, in clinical trials to date
there is no evidence of a relationship between the presence
of anti-insulin antibodies and HbA1c, hypoglycemia, or
hyperglycemia, nor is there evidence of any other adverse
clinical consequences (Fineberg et al 2005).
Small but consistent treatment group differences in
pulmonary function tests have been reported with inhaled
insulin, with pulmonary function reduced slightly in patients
assigned to Exubera (Hollander et al 2004; Quattrin et al
2004; Skyler et al 2005; Rosenstock et al 2005; Barnett et
al 2006). These differences occur early after treatment
initiation and are typically <1%–2% lower than those for
the comparator group, non-progressive in nature with safety
data now extending out to 4 years of therapy, not driven by
outliers, and are reversible following treatment
discontinuation (Dreyer et al 2004; Skyler et al 2004;
Odegard and Capoccia 2005; Riese et al 2005).
Patient-reported outcomes
Barriers to insulin therapy
Barriers to starting and maintaining treatment with
subcutaneous insulin have a major impact on patients’
abilities to self-manage their disease, and have resulted in
insulin being portrayed as a treatment of last resort (Hunt et
al 1997; Zambanini et al 1999; Korytkowski 2002;
Heinemann 2004; Hauber et al 2005). Typical barriers to
administering subcutaneous treatment arise due to both
injection-related and experiential concerns, with the latter
commonly described as psychological insulin resistance
(Hunt et al 1997; Funnell et al 2004). Thus, negative attitudes
relating to injection pain, concerns over correct technique
and inconvenience can lead to injection aversion (Hunt et
al 1997). Similarly, psychological insulin resistance may
arise from insulin therapy being perceived as a threat or
failure on a prior regimen, concerns about hypoglycemia
and other adverse effects, concerns over disease progression,
prior mention of insulin by the physician as a threat to
encourage compliance to oral therapies, and fear of treatment
failure (Hunt et al 1997; Korytkowski 2002; Funnell et al
2004; Heinemann 2004). In type 2 diabetes, an estimated
one-quarter of patients progressing to subcutaneous insulin
therapy refuse treatment once it has been prescribed
(Polonsky et al 2005). The presence of these barriers may
influence compliance, glycemic control and quality of life
(Zambanini et al 1999; Royle et al 2003).
Evidence for greater patient acceptance
of inhaled insulin
Encouraging positive patient attitudes and beliefs is essential
in diabetes management where patients require lifelong
treatment (Polonsky et al 2005). Noninvasive methods of
insulin delivery promise to return greater patient satisfaction
and treatment acceptance (Testa 2003). This in turn will
potentially see more patients achieving glycemic targets,
with consequent improvement in health outcomes, such as
those relating to microvascular and macrovascular
complications (Freemantle et al 2005).
Available patient satisfaction data have shown that
Exubera is associated with greater treatment satisfaction
relative to subcutaneous insulin in patients with type 1 or
type 2 diabetes. A 15-item questionnaire was developed to
gauge the level of patient satisfaction between Exubera and
conventional subcutaneous insulin therapy in two similar,
open-label, 3-month Phase II trials in patients with type 1
and type 2 diabetes. In both trials, subjects randomized to
Exubera also received a bedtime Ultralente injection, while
those randomized to subcutaneous insulin continued their
pre-study regimen (2–3 injections/day). In both studies, the
mean percentage improvement in overall patient satisfaction
score with Exubera was markedly greater than that with
subcutaneous insulin: 35% vs 12% (p=0.01) in subjects with
type 1 diabetes (Gerber et al 2001) and 38% vs 14% (p<0.05)
in subjects with type 2 diabetes (Cappelleri et al, 2002). To
evaluate long-term treatment satisfaction with Exubera a 1-
year extension was offered to subjects who had completed
the above 3-month studies (Rosenstock et al 2004). From
baseline to the end of the 1-year extension, subjects on
Exubera had a greater improvement than those on
subcutaneous insulin in global satisfaction (38.8% versus
4.0%, p<0.01), convenience/ease of use (42.4% vs –1.7%,
p<0.01), and social comfort (43.3% vs 12.7%, p=0.11).
Together, these data suggest that Exubera was preferred over
subcutaneous insulin and resulted in better patient
satisfaction in the short and longer term (at least 1 year).
In a 12-week study of 309 patients with type 2 diabetes
inadequately controlled by a sulfonylurea and either
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metformin or a thiazolidinedione, those who were
randomized to Exubera either alone or in addition to existing
therapy reported improved overall satisfaction relative to
baseline (Simonson et al 2001). In contrast, overall
satisfaction was unchanged in patients who continued to
receive oral antidiabetic agents alone. Changes from baseline
for subscales of advocacy, efficacy, general satisfaction and
preference were more favorable for Exubera compared with
oral agents alone while subscales of convenience, burden,
flexibility, hassle, life interference, social limitations, and
pain were not significantly different among treatments. The
only significant difference between Exubera in addition to
existing therapy and continued oral antidiabetic agents alone
was in the side-effects (weight gain and hypoglycemia)
satisfaction scale, which favored continued oral agents
alone. Improved endpoint HbA1c values as well as reduced
symptom interference were correlated with more favorable
satisfaction scores (Simonson et al 2001).
A recent study has demonstrated that inhaled insulin
promotes greater acceptance of insulin therapy in general
when inhaled insulin is available as a treatment option along
with oral antidiabetic agents and/or subcutaneous insulin
(Freemantle et al 2005). This was a randomized controlled
study of 779 patients with type 2 diabetes who were
inadequately controlled by dietary measures and/or oral
antidiabetic agents. Subjects were assigned to educational
information about the potential risks and benefits of either
standard treatment options of oral antidiabetic agents and/
or subcutaneous insulin, or inhaled insulin in addition to
standard treatment options. In the group offered information
about inhaled insulin as a treatment option, 43.2% opted
for a treatment that included insulin at a follow-up physician
consultation compared with just 15.5% of patients who were
informed about standard therapies only (Freemantle et al
2005) (Figure 3). Significantly fewer patients offered inhaled
insulin chose to make no change to their therapy compared
with patients offered standard treatments only, while fewer
patients in the former group opted for regimens containing
oral antidiabetic agents or subcutaneous insulin. This finding
suggests that the increased willingness of patients to adopt
an insulin-containing regimen when offered inhaled insulin
as a treatment option may increase the potential for glycemic
control with consequent reductions in diabetic
complications.
One final interesting observation has come from a
systematic review of clinical studies that investigated patient
acceptability for inhaled insulin versus injected insulin
(Royle et al 2003). The review included 6 open-label
randomized controlled trials lasting at least 12 weeks, which
enrolled a total of 1191 patients with type 1 or type 2
diabetes. Despite similar glycemic control achieved for
inhaled insulin and subcutaneous insulin, patient satisfaction
and quality of life measures were significantly greater in
the inhaled insulin group (five of the six studies were with
Exubera).
Conclusions
Large-scale studies such as UKPDS and DCCT have
demonstrated the importance of achieving strict glycemic
control in type 1 and type 2 diabetes in order to reduce the
likelihood of diabetes-related complications. Despite
guidelines recommending aggressive treatment to achieve
normal or near-normal blood glucose levels, most patients
remain inadequately controlled. Clearly, conventional
treatment options, particularly in relation to type 2 diabetes
in which insulin therapy is normally reserved as a last resort,
are inadequate for optimal disease management. The
perceived need among physicians for delaying insulin
therapy is of potential interest in the context of type 2
diabetes management and appears to be related to negative
attitudes held by many patients that are often exacerbated
by physicians, leading to injection aversion and
psychological insulin resistance. Conversely, it may be that
positive attitudes associated with early acceptance of insulin
Figure 3  Proportion of patients choosing indicated treatment based on
theoretical availability of standard therapy only or inhaled insulin in addition to
standard therapy. Patients with type 2 diabetes currently managed by dietary
measures and/or oral antidiabetic drugs were randomized to receive educational
information about the potential risks and benefits of standard therapy alone
(oral antidiabetic drugs and/or subcutaneous insulin, n=388) or inhaled insulin in
addition to standard therapy (n=391). In the group offered inhaled insulin as an
option, 43.2% of patients opted for a treatment that included insulin during a
patient-physician consultation compared with 15.5% of patients who were
offered standard therapy only (odds ratio 4.16 [95% CI, 2.93–5.95], p<0.0001).
Reprinted with permission from Freemantle N, et al. 2005. Availability of inhaled
insulin promotes greater perceived acceptance of insulin therapy in patients
with type 2 diabetes. Diabetes Care, 28:427–8. Copyright © American Diabetes
Association.
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therapy among patients and physicians alike may assist with
glycemic control and its likely benefits of minimizing or
preventing diabetes-related complications. Thus, early
insulin intervention is an important consideration in
tomorrow’s management guidelines, particularly as a high
proportion of patients will be increasingly younger at
diagnosis and will face living longer with the disease and
an earlier recourse to insulin therapy than a typical patient
currently living with the disease.
Inhaled insulin has been developed to address some of
the fundamental deficits of conventional subcutaneous
rapid-acting insulin analogs: namely, a lack of patient
satisfaction and convenience, needle aversion, and a
propensity for psychological insulin resistance. Inhaled
insulin products such as Exubera are an exciting
development in the management of diabetes since they
potentially avoid and certainly reduce the need for
subcutaneous injections while providing a physiologic
response to postprandial glucose. Compared with
subcutaneous insulin, Exubera demonstrates equivalent
efficacy in terms of HbA1c control, superior efficacy in terms
of fasting plasma glucose, and is well tolerated. In addition,
offering Exubera as an alternative treatment option to
subcutaneous insulin increases the number of patients
inadequately controlled on oral agents who are likely to
accept insulin as a therapy. This has the potential to improve
glycemic control, reduce diabetes-related complications and
decrease complication-related costs.
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